Preparation for treating diarrhea in youngsters of farm animals and method for its application

FIELD: veterinary science.

SUBSTANCE: the suggested preparation for treating diarrhea in farm animals youngsters contains bismuth salt in the form of bismuth-potassium ammonium citrate and, additionally, polyethylenoxide, moreover, preferably, it contains 1.5-2.5%-polyethylenoxide solution and 1.5-2.5%-bismuth-potassium ammonium citrate solution. The method for treating diarrhea deals with introducing the above-mentioned preparation once or twice daily for 1-2 d at the dosage of 1-75 ml/kg body weight. In young foxes it should be introduced at the dosage of 60-75 ml/kg body weight, in calves - at the dosage of 1-3 ml/kg body weight, in lambs - at the dosage of 2-3 ml/kg body weight. Application of the present complex preparation and therapeutic method enables to shorten terms of therapy by 1.5-2 times, decreases expenses for therapy by 3-5 times and provides decreased toxicological impact the preparation upon animal body.

EFFECT: higher efficiency of therapy.

6 cl, 3 ex, 2 tbl

 

The invention relates to the field of veterinary medicine, in particular to the means and methods of treatment of diarrhea in farm animals.

Known bismuth preparations of bismuth salicylate main, kseroforma (Dccallow et al. "Drugs in veterinary medicine". - M.: Kolos, 1977. - P.132-133), Medmaravis. "Drugs". - M.: Medicine, 1986. - S-343), which have local, surface-active astringent action of bismuth ions on the inflamed surface of the gastrointestinal tract. Upon contact with the inflamed surface of the gastrointestinal tract salt of bismuth contact surface protein structures of the cell and form albuminate, and the film formed in inflammation promotes rapid regeneration of damaged tissue structures. Upon contact of bismuth ions with surface structures of microorganisms is their inactivation, which leads to loss of adhesive-pathogenic properties of microorganisms.

The disadvantage of these drugs and methods of their use is that they all have low solubility in water and require mandatory introduction in the form of mixtures with mucous or vegetable binders, bolus or pill, which hinders their production used in agriculture. Some of them (kseroforma) use who are primarily externally in the form of powders and ointments, while ingestion is denied due to toxicity of the drug.

The closest solution adopted for the prototype, is the preparation of bismuth nitrate basic and a method for its use. The drug used in the treatment of peptic ulcer of the stomach and small intestine in the form of powder or tablets. The drug has antiseptic, anti-inflammatory, astringent action has a beneficial effect on inflamed mucous membrane of the stomach and intestines, showing antimicrobial and antitoxic properties (Yeshow. Pharmacology, 1952. - S-358, Dccallow et al. "Drugs in veterinary medicine". - M.: Kolos, 1977. - P.132-133, Medmaravis. "Drugs". - M.: Medicine, 1986. - S-343).

The disadvantage of the drug is that it is applied in the form of powder or tablets, have a low solubility in water, which greatly reduces its absorption by the body, and hence therapeutic efficacy. The method of application (mixing with mucilaginous decoction of plant origin preparation of medicine and boles) preparation time-consuming, which makes its use in agricultural production, in particular on large livestock farms and complexes, farms with large numbers of animals.

The objective of the proposed solutions is to expand the range of tools the La treatment of diarrhoea of young farm animals bacterial etiology.

The technical result of the invention is to reduce the duration of treatment and Toxicological effects of the drug on the body of the animal.

The technical problem is solved by the fact that in a well-known drug for the treatment of diarrhoea of young farm animals according to the invention uses a product containing a salt of bismuth, characterized in that it additionally contains potassium hydroxide, aqueous ammonia and citric acid, which significantly improves its solubility (preparation of aqueous solutions), and hence therapeutic effect.

The technical problem is solved by the fact that to enhance and prolong therapeutic effect he further comprises a polyethylene oxide, which when dissolved in water is a mucous form, with increased permeability and coating properties.

The goal of the project also is solved in that a method of treatment of diarrhea of young farm animals, including the introduction of the drug, characterized in that the drug is administered in the form of an aqueous solution with an aqueous solution of polyethylene oxide.

In addition, the technical problem is solved by the fact that the components are taken in the following respects: 1,5-2,5% solution of the drug salt of bismuth and 1.5-2.5% solution of polyethylene oxide.

Sown the feature of the invention consists in the in the known method of treatment comprising administration of the drug, according to the invention sick animals feeding in the following doses: Fox the drug is administered at a dose of 60-75 ml/kg body weight 1-2 times daily for 1-2 days; calves, the drug is administered in a dose of 1-3 ml/kg body weight 1-2 times daily for 1-2 days; the lambs the drug is administered 2-3 ml/kg body weight 1-2 times daily 1-2 days.

The drug is prepared as follows. To add distilled water when mixing potassium hydroxide and citric acid. To the resulting solution was added with stirring, bismuth citrate, and then aqueous ammonia to pH 8 and are dissolved in 3 hours. The resulting solution bismuth-potassium ammonium citrate diluted with distilled water and dried by spraying with obtaining crystalline powder. The resulting powder was mixed with an aqueous solution of polyethylene oxide, pre-mix in the water.

Concentrated form of the drug in a volume of 200 ml or 400 ml stored at a temperature of +4(+8)°within 2 years. The drug in a dissolved state is stored without adding preservatives in a cool dark place for 1 year.

The invention is illustrated by the following examples using the drug for a therapeutic effect in farm animals.

Example 1.

Therape the political effectiveness of a new drug, containing 1.5-2% solution of bismuth-potassium ammonium citrate and polyethylene oxide was studied when gastroenteritic young silver foxes 5-6 months of age.

The drug was drinking 5 experimental groups Fox cubs at a concentration of 1-5%solution at a dose (n=5) 60-75 ml per 1 kg/body weight, 1-2 times a day. As a control was matched group of Fox cubs on the principle of analogs whose treatment was carried out by rivalling according to the instruction for use. Doses in experimental groups were taken from the prototype drug of bismuth nitrate basic (table 1).

Table 1. Determination of the optimal concentration of the drug Eterovic and duration of treatment for diarrhoea Fox
No.no groupDose ml/kg body weightThe concentration of the drug, %The course of treatment, DNThe term parabolani, DN
1group 160-750.5 to 1.032,0±0.6
2group 260-751,5-2,01-21,5±0.2
3group 360-75the 2.0-3.01-21,5+0.2
4group 460-75 3.0-4.01-21,4+0.2
5group 560-75of 4.0-5.01-21,4±0.1
6Control (lifecycles)0,1512.6±0.2

The optimal scheme, the ratio between therapeutic effect and cost of the drug, was treated in group No. 2. The average time of recovery in experimental groups to 1.57±0.14 day, 1.5-2 times less than in the control group, where the treatment was performed antibacterial drug.

Laboratory examination of blood serum Fox cubs showed an increase lysozyme and bactericidal activity in the experimental group No. 2 (use of salts of bismuth) compared to control (use of antibiotic). Decreased levels of protein, which may indicate a weakening of the diarrhoeal syndrome. Also showed a significant increase in alpha (55%) and beta- (20%) and a decrease in gamma-globulin (27%), which may indicate a decrease in the intensity of infection.

Example 2.

therapeutic efficacy of a new drug, containing 1.5-2% solution of bismuth-potassium ammonium citrate and polyethylene oxide was examined in the gastroenteritis of young cattle. This was the formed 6 groups (n=5), 5 experimental (drug use) and control (group, where he used the usual treatment regimen adopted in the household). In the experience were used calves black-motley breed 1-2,5 months. age. Calves of the control group was treated with aquilonem 0.1 ml/kg body weight, subcutaneously 1 time per day. Doses in experimental groups were taken from the prototype drug of bismuth nitrate basic.

Calves from the experimental group were drinking the preparation of salts of bismuth 1-5%solution of 1-3 ml/kg body weight, 1-2 times a day. Recovery period in the control and experimental groups respectively was 3.0±0.2 and 2,6±0.2 days. The optimal scheme, the ratio between therapeutic effect and cost of the drug, was treated in group 2 (table 2).

tr>
Table 2. Determination of the optimal concentration of the drug Eterovic and duration of treatment for diarrhoea of calves
No.no groupDose ml/kg body weightThe concentration of the drug, %The course of treatment, DNThe term parabolani, DN
1group 11-31,0-1,533,8±0,6
2group 21-31,5-2,01-22,6±0,2
3group 31-32,0-3,01-22,5±0,2
4group 41-33,0-4,01-22,5±0,2
5group 51-34,0-5,01-22,4±0,1
6Control (equilon)0,151-23,0±0,2

Analyzing the dynamics of biochemical changes in the serum of animals in experimental groups before and after application of the test drug bismuth, may be noted the stabilization of homeostatic indicators in animals compared to control animals. Thus, the decreased level of circulating immune complexes, which indicates a decrease in the intensity of infection in animals. Also changed significantly interest redistribution in the protein fractions of blood (decreased gamma globulin and increased beta - and alpha-globulin fractions), which may indicate a decrease in the infectious process. A direct measure of the amplification of nonspecific resistance can be an increase in bactericidal and lysozyme activity of serum. Stabilization of water-salt exchange can be traced in the norm is Itachi indicators Alp, alkaline reserve, calcium and inorganic phosphorus. Normalization of metabolic processes can be seen in the increase in carotene, lowering of cholesterol, asparaginases and alanineaminotransferase compared to control animals.

Example 3.

therapeutic efficacy of a new drug, containing 1.5-2% solution of bismuth-potassium ammonium citrate and polyethylene oxide, tested on newborn lambs with the clinical picture of colibacillosis.

A control group of calves (n=10) was treated with gentamicina and streptomycin as directed to the use of drugs. Four experimental groups (n=10) lambs were drinking the preparation of salts of bismuth in the form of 1.5-2.5%aqueous solution at doses of 1.0-3.0 ml/kg body weight. The most pronounced therapeutic efficacy of the drug, confirmed a higher rate stabilization indicators of homeostasis of the organism was observed in the group of the lambs, where treatment is carried out at a dose of 2.0-3.0 ml/kg body weight 1-2 times daily. In this experimental group, the average recovery time was 1.8 days in the complete absence of mortality, whereas in the control group are marked case 1 (10%) of the head, the average recovery time was 5.1 days.

Use this comprehensive drug and treatment can reduce the duration of treatment in 1,5-2 times, reduce treatment costs 3-5 times. Yes the hydrated method of treatment does not exert toxic effects on macro, observed in antibiotic therapy, and is not conducive to the emergence of antibiotic-resistant strains.

The ratio in the preparation of solutions of bismuth-potassium ammonium citrate and polyethylene oxide has no effect on the reduction of treatment time and Toxicological effects of the drug on the body of the animal, as with any ratio of active ingredients it has a higher permeability and has a coating properties, in addition, the drug contains the active substances in low concentrations and it is used in small concentrations (0.5-5.0 percent).

1. Drug for the treatment of diarrhoea of young farm animals, including a salt of bismuth, characterized in that it contains a salt of bismuth in the bismuth-potassium ammonium citrate, and optionally polyethylene oxide.

2. The preparation according to claim 1, characterized in that it contains 1.5 to 2.5%solution of polyethylene oxide and 1.5 to 2.5%solution of bismuth-potassium ammonium citrate.

3. The method of treatment of diarrhea of young farm animals, including the introduction of a preparation containing a salt of bismuth, characterized in that the quality of a product containing a salt of bismuth, drug use according to claim 1 or 2, which is feeding 1-2 times a day for 1-2 days at a dose of 1-75 ml/kg body weight.

4. The method according to claim 3, characterized in that Fox drug feeding in the Oze 60-75 ml/kg body weight.

5. The method according to claim 3, characterized in that the calves drug is feeding at a dose of 1-3 ml/kg body weight.

6. The method according to claim 3, characterized in that the lambs drug is feeding at a dose of 2-3 ml/kg body weight.



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: composition comprises raw protein 10 to 42% by mass, fat 4 to 30% by mass, total dietetic cellular tissue 1to 25% by mass and source of additional nutrient fibers. Method involves keeping animals on the like dietary intake during time required for controlling hair excretion with feces and preventing from trichobezoar formation.

EFFECT: enhanced effectiveness of prophylaxis and treatment.

22 cl, 12 tbl

The invention relates to veterinary medicine and can be used for the prevention of gastrointestinal disease of young cattle

The invention relates to medicine, gastroenterology, and can be used for the treatment of diseases associated with infection of the colon bacterium C. difficile, and the formation of colonies resistant to vancomycin enterococci
The invention relates to medicine

The invention relates to biotechnology and characterizes the phytase, the DNA fragment encoding the phytase, an expression vector containing the DNA fragment

The invention relates to veterinary
The invention relates to biotechnology
The invention relates to medicine, namely to diseases of the digestive system, and can be used for treatment of a dysbacteriosis of intestines

The invention relates to a new 2-{4-[4-(4,5-dichloro-2-Mei-1-yl)butyl]-1-piperazinil}-5-torpedinidae formula I (see

The invention relates to pharmaceutical

The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen
The invention relates to medicine, specifically to medicines antidiarrheal action

The invention relates to the field of organic chemistry and medicine and relates to new quinoline derivatives of General formula I, where R represents unsubstituted C1-C3-alkyl or C2-C3alkenyl; R1is cyano, which are agonists alpha-2-adrenergic receptors and can be used when obtaining drugs suitable for the treatment of nasal congestion, glaucoma, diarrhea, asthma

The invention relates to medicine, specifically to experimental physiology, pharmacology and pathophysiology related to the possibility of modeling violations of motor-evacuation function of the intestines - constipation

FIELD: medicine, oncology.

SUBSTANCE: invention relates to a method for assay of efficacy on post-operative intrathecal chemotherapy of patients with intracerebral malignant tumors. Method involves determination of total protein level in cerebrospinal fluid before and after carrying out chemotherapy in autoliquor. Increase of the level of total protein by 5.6-6.3 times indicates on effectiveness of the post-operative chemotherapy. Method provides the objective evaluating dynamic of cytolysis of tumor cells that is the reliable method for estimation of efficacy of indicated treatment.

EFFECT: enhanced and improved method for treatment.

1 ex

FIELD: experimental medicine, oncology, biology.

SUBSTANCE: invention relates to a method for inhibition of tumor growth using radiation therapy as ionizing radiation with additional administration of mixture of octa-4,5-carboxyphthalocyanine sodium cobalt salt or oxocobalamine with sodium ascorbate in the ratio = (1:10)-(1:30). Method of combined using irradiation and indicated mixture of substances provides enhancing the effectiveness of anti-tumor treatment resulting to 70-100% recovery of experimental animals and reducing radiation loading and toxicity.

EFFECT: improved method for inhibition.

2 tbl, 3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: after keeping during pharmaceutically acceptable period oxaliplatinum is placed in transparent, colorless and residue-free solution at concentration of, at least, 7 mg/ml, and a solvent contains sufficient quantity of, at least, one hydroxylated derivative chosen among of 1.2-propandiol, glycerol, maltite, saccharose and inositol. The innovation describes the way to obtain such a preparation. The preparation is stable during pharmaceutically acceptable period of time, that is it remains transparent, colorless and free of any residue within the range of 2-30 C that could be available during its transportation, storage and/or any handling.

EFFECT: higher efficiency of application.

14 cl, 6 ex, 4 tbl

FIELD: pharmaceutics, veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating hypomicroelementosis in different farm and domestic animals, furred animals, and, also, for enhancing the growth in animals, and treating a number of specific diseases and, also, for maintaining microelemental composition of feedstuffs. The suggested preparation includes chelated complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with organic ligand of complexone type and water. According to the innovation as a chelation ligand it contains trisodium salt of methionine succinic (α-amino-γ-methylthiobutyric-N-succinic) acid at a certain ratio of components. The innovation provides to obtain preparation in soluble form being capable to be well digested by the animal.

EFFECT: higher efficiency.

FIELD: experimental medicine.

SUBSTANCE: on should introduce solution into fracture area at the following ratio of ingredients, g/l: 1-hydroxyethylidenediphosphonic acid 1.80 - 2.06, water-free calcium chloride 1.44 - 2.22, gadolinium (III) nitrate hexahydrate 0.30 - 0.40, dysprosium (III) chloride hexahydrate 0.038 - 0.076, moreover, solution's pH corresponds to 7.3 - 7.8. The present innovation enables to shorten the process of bony tissue regeneration in the site of its lesion or defect and, also, shorten the period for restoring normal physiological function of traumatized bone.

EFFECT: higher efficiency of regeneration.

22 ex, 1 tbl

The invention relates to medicine and can be used in the treatment of nephropathy in children in the neonatal period
Up!